Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition

Young Dong Yoo; Dae Hee Lee; Hyunjoo Cha-Molstad; Hyungsin Kim; Su Ran Mun; Changhoon Ji; Seong Hye Park; Ki Sa Sung; Seung Ah Choi; Joonsung Hwang; Deric M. Park; Seung Ki Kim; Kyung Jae Park; Shin Hyuk Kang; Sang Cheul Oh; Aaron Ciechanover; Yong J. Lee; Bo Yeon Kim; Yong Tae Kwon

doi:10.15252/embr.201642360

Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition

Young Dong Yoo, Dae Hee Lee, Hyunjoo Cha-Molstad, Hyungsin Kim, Su Ran Mun, Changhoon Ji, Seong Hye Park, Ki Sa Sung, Seung Ah Choi, Joonsung Hwang, Deric M. Park, Seung Ki Kim, Kyung Jae Park, Shin Hyuk Kang, Sang Cheul Oh, Aaron Ciechanover, Yong J. Lee, Bo Yeon Kim, Yong Tae Kwon

Department of Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

17 Citations (Scopus)

Abstract

Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC₅₀, 27–70 nM) compared with their differentiated controls (IC₅₀, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.

Original language	English
Pages (from-to)	150-168
Number of pages	19
Journal	EMBO Reports
Volume	18
Issue number	1
DOIs	https://doi.org/10.15252/embr.201642360
Publication status	Published - 2017 Jan 1

Keywords

apoptosis
c-Jun N-terminal kinase
glioma stem cells
proteasome inhibitors
ubiquitin proteasome system

ASJC Scopus subject areas

Biochemistry
Molecular Biology
Genetics

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.15252/embr.201642360

Cite this

Yoo, Y. D., Lee, D. H., Cha-Molstad, H., Kim, H., Mun, S. R., Ji, C., Park, S. H., Sung, K. S., Choi, S. A., Hwang, J., Park, D. M., Kim, S. K., Park, K. J., Kang, S. H., Oh, S. C., Ciechanover, A., Lee, Y. J., Kim, B. Y., & Kwon, Y. T. (2017). Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition. EMBO Reports, 18(1), 150-168. https://doi.org/10.15252/embr.201642360

@article{ec7c8233322b4a2b8ab76a699ac941f2,

title = "Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition",

abstract = "Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC50, 27–70 nM) compared with their differentiated controls (IC50, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.",

keywords = "apoptosis, c-Jun N-terminal kinase, glioma stem cells, proteasome inhibitors, ubiquitin proteasome system",

author = "Yoo, {Young Dong} and Lee, {Dae Hee} and Hyunjoo Cha-Molstad and Hyungsin Kim and Mun, {Su Ran} and Changhoon Ji and Park, {Seong Hye} and Sung, {Ki Sa} and Choi, {Seung Ah} and Joonsung Hwang and Park, {Deric M.} and Kim, {Seung Ki} and Park, {Kyung Jae} and Kang, {Shin Hyuk} and Oh, {Sang Cheul} and Aaron Ciechanover and Lee, {Yong J.} and Kim, {Bo Yeon} and Kwon, {Yong Tae}",

note = "Funding Information: We thank Drs. Daniel Finley, Jon Clardy (Harvard University), and Jae J. Song (Yonsei University) for providing us with PS341, salinosporamide A, and TRAIL, respectively; Kyoung Tae Seo (Soongsil University) and Su Jin Yoo (University of Wisconsin-Madison) for technical assistance; and Edward Kwak (Viagen Biotech Inc., USA) for editorial assistance. This work was supported by the SNU Nobel Laureates Invitation Program (to A.C.), the Basic Science Research Programs of the NRF funded by the Ministry of Science, ICT and Future Planning (MSIP) (NRF-2016R1A2B3011389 to Y.T.K. and 2015R1D1A1A01058303 to D.H.L.) and the Ministry of Education (NRF-2013R1A1A2058983 to Y.D.Y), Seoul National University Hospital (to Y.T.K.), the National Cancer Institute grant CA140554 (to Y.J.L), the World Class Institute (WCI) Program of the NRF funded by the MSIP (WCI 2009-002 to B.Y.K.), the R&D Convergence Program (CAP-16-03-KRIBB to B.Y.K.) of NST of Korea, the Bio and Medical Technology Development Program (NRF-2014M39Ab5073938 to B.Y.K.) of MSIP and KRIBB Research Initiative Program, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) (to A.C.), and the Israel Science Foundation (ISF) (to A.C.). A.C. is an Israel Cancer Research Fund (ICRF), USA Professor. Publisher Copyright: {\textcopyright} 2016 The Authors",

year = "2017",

month = jan,

day = "1",

doi = "10.15252/embr.201642360",

language = "English",

volume = "18",

pages = "150--168",

journal = "EMBO Reports",

issn = "1469-221X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition

AU - Yoo, Young Dong

AU - Lee, Dae Hee

AU - Cha-Molstad, Hyunjoo

AU - Kim, Hyungsin

AU - Mun, Su Ran

AU - Ji, Changhoon

AU - Park, Seong Hye

AU - Sung, Ki Sa

AU - Choi, Seung Ah

AU - Hwang, Joonsung

AU - Park, Deric M.

AU - Kim, Seung Ki

AU - Park, Kyung Jae

AU - Kang, Shin Hyuk

AU - Oh, Sang Cheul

AU - Ciechanover, Aaron

AU - Lee, Yong J.

AU - Kim, Bo Yeon

AU - Kwon, Yong Tae

N1 - Funding Information: We thank Drs. Daniel Finley, Jon Clardy (Harvard University), and Jae J. Song (Yonsei University) for providing us with PS341, salinosporamide A, and TRAIL, respectively; Kyoung Tae Seo (Soongsil University) and Su Jin Yoo (University of Wisconsin-Madison) for technical assistance; and Edward Kwak (Viagen Biotech Inc., USA) for editorial assistance. This work was supported by the SNU Nobel Laureates Invitation Program (to A.C.), the Basic Science Research Programs of the NRF funded by the Ministry of Science, ICT and Future Planning (MSIP) (NRF-2016R1A2B3011389 to Y.T.K. and 2015R1D1A1A01058303 to D.H.L.) and the Ministry of Education (NRF-2013R1A1A2058983 to Y.D.Y), Seoul National University Hospital (to Y.T.K.), the National Cancer Institute grant CA140554 (to Y.J.L), the World Class Institute (WCI) Program of the NRF funded by the MSIP (WCI 2009-002 to B.Y.K.), the R&D Convergence Program (CAP-16-03-KRIBB to B.Y.K.) of NST of Korea, the Bio and Medical Technology Development Program (NRF-2014M39Ab5073938 to B.Y.K.) of MSIP and KRIBB Research Initiative Program, the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF) (to A.C.), and the Israel Science Foundation (ISF) (to A.C.). A.C. is an Israel Cancer Research Fund (ICRF), USA Professor. Publisher Copyright: © 2016 The Authors

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC50, 27–70 nM) compared with their differentiated controls (IC50, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.

AB - Although proteasome inhibitors (PIs) are used as anticancer drugs to treat various cancers, their relative therapeutic efficacy on stem cells vs. bulk cancers remains unknown. Here, we show that stem cells derived from gliomas, GSCs, are up to 1,000-fold more sensitive to PIs (IC50, 27–70 nM) compared with their differentiated controls (IC50, 47 to »100 μM). The stemness of GSCs correlates to increased ubiquitination, whose misregulation readily triggers apoptosis. PI-induced apoptosis of GSCs is independent of NF-κB but involves the phosphorylation of c-Jun N-terminal kinase as well as the transcriptional activation of endoplasmic reticulum (ER) stress-associated proapoptotic mediators. In contrast to the general notion that ER stress-associated apoptosis is signaled by prolonged unfolded protein response (UPR), GSC-selective apoptosis is instead counteracted by the UPR. ATF3 is a key mediator in GSC-selective apoptosis. Pharmaceutical uncoupling of the UPR from its downstream apoptosis sensitizes GSCs to PIs in vitro and during tumorigenesis in mice. Thus, a combinational treatment of a PI with an inhibitor of UPR-coupled apoptosis may enhance targeting of stem cells in gliomas.

KW - apoptosis

KW - c-Jun N-terminal kinase

KW - glioma stem cells

KW - proteasome inhibitors

KW - ubiquitin proteasome system

UR - http://www.scopus.com/inward/record.url?scp=85006983243&partnerID=8YFLogxK

U2 - 10.15252/embr.201642360

DO - 10.15252/embr.201642360

M3 - Article

C2 - 27993939

AN - SCOPUS:85006983243

VL - 18

SP - 150

EP - 168

JO - EMBO Reports

JF - EMBO Reports

SN - 1469-221X

IS - 1

ER -

Glioma-derived cancer stem cells are hypersensitive to proteasomal inhibition

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this